Uni Eropa - Belanda - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilepsies, gedeeltelijk - van anti-epileptica, - lacosamide ucb is geïndiceerd als monotherapie en adjuvante therapie bij de behandeling van partieel beginnende aanvallen met of zonder secundaire generalisatie bij volwassenen, adolescenten en kinderen vanaf 4 jaar en ouder met epilepsie.

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

orion corporation - emulsie voor injectie - propofol - honden; katten

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bouchara-recordati immeuble le wilson 70, avenue du général de gaulle 92800 puteaux (frankrijk) - atorvastatine calcium 3-water 10,9 mg/stuk samenstelling overeenkomend met ; atorvastatine 10 mg/stuk ; ezetimib 10 mg/stuk - tablet - calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201), calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201)

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bouchara-recordati immeuble le wilson 70, avenue du général de gaulle 92800 puteaux (frankrijk) - atorvastatine calcium 3-water 21,7 mg/stuk samenstelling overeenkomend met ; atorvastatine 20 mg/stuk ; ezetimib 10 mg/stuk - tablet - calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201), calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201)

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bouchara-recordati immeuble le wilson 70, avenue du général de gaulle 92800 puteaux (frankrijk) - atorvastatine calcium 3-water 43,4 mg/stuk samenstelling overeenkomend met ; atorvastatine 40 mg/stuk ; ezetimib 10 mg/stuk - tablet - calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201), calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201)

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bouchara-recordati immeuble le wilson 70, avenue du général de gaulle 92800 puteaux (frankrijk) - atorvastatine calcium 3-water 86,8 mg/stuk samenstelling overeenkomend met ; atorvastatine 80 mg/stuk ; ezetimib 10 mg/stuk - tablet - calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201), calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hyprolose (e 463) ; lactose 1-water ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201)

Belgia - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kora corporation t/a kora healthcare ltd. - magnesiumcitraat nonahydraat 817 mg - eq. magnesium 97,2 mg - tablet - 97 mg - magnesiumnonahydraat 817 mg - magnesium citrate

Uni Eropa - Belanda - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - van anti-epileptica, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Uni Eropa - Belanda - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft rejection - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Belgia - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kora corporation t/a kora healthcare ltd. - magnesiumaspartaatdihydraat 3246 mg - eq. magnesium 243 mg - poeder voor drank - 243 mg - magnesiumaspartaatdihydraat 3246 mg - magnesium aspartate